MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
8.67
-0.25
-2.80%
Opening 11:39 02/09 EST
OPEN
8.92
PREV CLOSE
8.92
HIGH
9.18
LOW
8.61
VOLUME
811.16K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
1.775
MARKET CAP
1.50B
P/E (TTM)
-4.9540
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLAY last week (0202-0206)?
Weekly Report · 6h ago
$207B Market Shift: The Race for Fast Track Approval in Oncology
Barchart · 4d ago
Relay Therapeutics Shares Rise After Breakthrough Therapy Designation for Zovegalisib
Dow Jones · 6d ago
Relay Therapeutics Wins FDA Breakthrough Therapy Designation
TipRanks · 6d ago
Relay Therapeutics announces U.S. FDA granted BTD to zovegalisib
TipRanks · 6d ago
Relay Therapeutics Wins FDA Breakthrough Therapy Designation for Zovegalisib in Advanced Breast Cancer
Reuters · 6d ago
FDA Grants Breakthrough Therapy Designation to Relay Therapeutics' Zovegalisib for Advanced Breast Cancer
Reuters · 6d ago
RELAY THERAPEUTICS ANNOUNCES ZOVEGALISIB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PIK3CA-MUTANT, HR+/HER2- ADVANCED BREAST CANCER
Reuters · 6d ago
More
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.